Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07136324 · ClinicalTrials.gov registry record
Safety and Efficacy of EUS-RFA in the Treatment of Pancreatic Lesions: A Prospective Registry
A clinical trial of Pancreatic Cyst, sponsored by The University of Texas Health Science Center, Houston.
- Active
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT07136324: Active study of Pancreatic Cyst, sponsored by The University of Texas Health Science Center, Houston.
NCT07136324 is a study of Pancreatic Cyst that is active but no longer recruiting, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 100 participants, below the 545-participant average among 18 other Pancreatic Cyst trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07136324, a study of Pancreatic Cyst, is active but no longer recruiting, sponsored by The University of Texas Health Science Center, Houston.
- ACTIVE NOT RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Purpose: The purpose of this registry is to track the clinical outcomes and progression of patients with pancreatic lesions receiving endoscopic ultrasound (EUS)-based radiofrequency ablation (RFA) therapy. Research Design: This study is a 7-year, single-center prospective registry study with annual follow up. Patients with pancreatic lesions undergoing EUS-guided RFA treatment will be studied. There will be no deviation from standard of care procedures. Procedures to be Used: Following recruitment into the program, eligible patients will undergo EUS-RFA for the treatment of their pancreatic lesion and/or malignancy as part of their standard of care. Endoscopic Intervention: The EUS-guided intervention will be performed based on a clinical decision. The data will be collected for research purposes. Briefly, the procedure involves advancing a 19-gauge EUS-RFA catheter into the target lesion under EUS-guidance. RFA energy is then applied in 2-10 cycles with each cycle lasting about 10 to 30 seconds and the power setting ranging from 10 to 30 Watts. The same physician who performs the initial EUS-RFA procedure will be responsible for subsequent EUS-RFA procedures. Risks and Potential Benefits: This is a minimal-risk study with associated physical risks being those part of routine standard of care. Additional risks associated with this study include the possible loss of confidentiality if the patient data or information is inadvertently disclosed outside of this study, risks associated with obtaining blood samples, and risks associated with obtaining tissue samples via biopsy. However, all information will be kept strictly confidential and will be used only for research purposes by the listed investigators. Patients will not receive any additional benefit from the study aside from those received as part of standard of care.
Primary Outcome
The efficacy of EUS-RFA in inducing the remission of functional, pre-malignant, and/or malignant solid/cystic pancreatic lesions.
Conditions Studied
Interventions
- DEVICE EUS-guided RFA treatment
Study Locations (1)
Texas
- Memorial Hermann Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-10-30 |
| Est. Completion | 2028-07-01 |
What the registry record for NCT07136324 still lists
NCT07136324 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 545-participant average among 18 other Pancreatic Cyst trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Pancreatic Cyst appearing as the primary indexed condition, and to 1 intervention - of which EUS-guided RFA treatment is the first listed.
NCT07136324 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07136324 about?
NCT07136324 is a clinical study titled "Safety and Efficacy of EUS-RFA in the Treatment of Pancreatic Lesions: A Prospective Registry". Purpose: The purpose of this registry is to track the clinical outcomes and progression of patients with pancreatic lesions receiving endoscopic ultrasound (EUS)-based radiofrequency ablation (RFA) therapy. Research Design: This study is a 7-year, single-center prospective registry study with annua...
What is the current status of trial NCT07136324?
This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2018-10-30. Estimated completion is 2028-07-01.
What conditions does trial NCT07136324 study?
This clinical trial studies the following conditions: Pancreatic Cyst.
What interventions are being tested in trial NCT07136324?
The interventions under investigation include: EUS-guided RFA treatment (DEVICE).
Who is sponsoring clinical trial NCT07136324?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07136324 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cyst
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07136324's enrollment target sits among peer trials
100 12th of 18 higher than 7 of 18 other Pancreatic Cyst trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cyst trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms
RECRUITING
-
EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
RECRUITING · NA
-
Evaluation of Pancreatic Cystic Lesions Via EUS-guided Fine Needle Aspiration With and Without Micro Forceps Biopsies
RECRUITING · NA
-
UCSF PANC Cyst Registry
RECRUITING
-
PROMs After Pancreatectomy
RECRUITING
-
Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI